Arrowhead Pharmaceuticals Inc.
ARWR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.46B
Close$
$-3.88
106.3% downside
Current Fair Value
106.3% downsideOvervalued by 106.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.46 Billion |
|---|---|
| Enterprise Value | $9.37 Billion |
| Earnings per Share | $-0.01 |
| Beta | 1.3 |
| Outstanding Shares | 143,378,000 |
Return
| Return on Equity | -68.73% |
|---|---|
| Return on Assets | -15.15% |
| Return on Invested Capital | -10.77% |
Valuation & Multiples
| P/E Ratio | -26.74 |
|---|---|
| PEG | -246.13 |
| Price to Sales | 15.41 |
| Price to Book Ratio | 20.55 |
| Enterprise Value to Revenue | 13.99 |
| Enterprise Value to EBIT | -47.54 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.19
Consensus analyst estimateRevenue Estimate
$47.89 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.52
Consensus analyst estimateRevenue Estimate
$61.18 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 43.59% |
|---|---|
| Total Calls | 500▼ 99.97% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.61%▼ 82.26% |
|---|---|
| Total Invested | $151.12M▼ 98.46% |
| Investors Holding | 122▼ 401.00% |
About Arrowhead Pharmaceuticals Inc.
711 employees
CEO: Christopher Anzalone
Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interf...